PRAN vs. CPIX, BIOR, MEIP, NRSN, SYBX, ONTX, BFRG, YMTX, LUMO, and GDTC
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Cumberland Pharmaceuticals (CPIX), Biora Therapeutics (BIOR), MEI Pharma (MEIP), NeuroSense Therapeutics (NRSN), Synlogic (SYBX), Onconova Therapeutics (ONTX), Bullfrog AI (BFRG), Yumanity Therapeutics (YMTX), Lumos Pharma (LUMO), and CytoMed Therapeutics (GDTC). These companies are all part of the "medical" sector.
Alterity Therapeutics (NASDAQ:PRAN) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Cumberland Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Alterity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alterity Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
3.6% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Alterity Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -15.87%. Cumberland Pharmaceuticals' return on equity of 6.84% beat Alterity Therapeutics' return on equity.
In the previous week, Cumberland Pharmaceuticals had 45 more articles in the media than Alterity Therapeutics. MarketBeat recorded 45 mentions for Cumberland Pharmaceuticals and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.18 indicating that Alterity Therapeutics is being referred to more favorably in the media.
Alterity Therapeutics received 1 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 57.67% of users gave Alterity Therapeutics an outperform vote while only 45.28% of users gave Cumberland Pharmaceuticals an outperform vote.
Summary
Cumberland Pharmaceuticals beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
